THNRvsETF 2ETF Comparison
VS
ETF 2
Choose a second ETF to run a side-by-side ETF comparison with THNR, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
THNR performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 07/17/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | THNR ETF 2 | +5.75%– | +2.78%– | +1.99%– | +14.21%– | n/a– | n/a– |
| Flows | THNR ETF 2 | +$769K– | +$769K– | +$2M– | +$2M– | -– | -– |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | THNR ETF 2 | +19.59%– | +18.10%– | n/a– | n/a– |
| Max drawdown | THNR ETF 2 | -5.40%– | -12.38%– | n/a– | n/a– |
| Max drawdown duration | THNR ETF 2 | 67d– | 160d– | n/a– | n/a– |
Trading data
THNR | ETF 2 | |
Last sale 7/17/2026 at 1:30 PM | $25.72 | – |
| Previous close 07/16/2026 | $25.83 | – |
| Consolidated volume 07/16/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of June 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
THNR | ETF 2 | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 7/17/2026 at 1:30 PM
Live
Closed
THNR | ETF 2 | |
|---|---|---|
| Last price | $25.72 | – |
| 1D performance | -0.41% | – |
| AuM | $5.14 M | – |
| E/R | 0.59% | – |
Characteristics
THNR | ETF 2 | |
|---|---|---|
| Management strategy | Passive | – |
| Provider | Amplify ETFs | – |
| Benchmark | VettaFi Weight Loss Drug & Treatment Index | – |
| N° of holdings | 20 | – |
| Asset class | - | – |
| Trailing 12m distribution yield | Join | Join |
| Inception date | May 21, 2024 | – |
| ESG | No | – |
Advertisement
Exposure
Countries
THNR
USA
51.87%
Denmark
16.32%
China
10.1%
Japan
9.42%
Other
12.29%
ETF 2
Sectors
THNR
Healthcare
98.8%
Other
1.2%
ETF 2
Advertisement
Diversification
THNR
Total weight of top 15 holdings out of 15
90.83%
ETF 2
–
Top 15 holdings
Data as of May 31, 2026
THNR
Novo Nordisk A/S
14.39%
Eli Lilly & Co.
13.48%
Arrowhead Pharmaceuticals, Inc.
6.19%
Amgen, Inc.
6.02%
Regeneron Pharmaceuticals, Inc.
5.60%
Chugai Pharmaceutical Co., Ltd.
5.24%
Roche Holding AG
5.15%
Merck & Co., Inc.
5.05%
Innovent Biologics, Inc.
4.88%
AstraZeneca PLC
4.76%
Pfizer Inc.
4.70%
AbbVie, Inc.
4.63%
Shionogi & Co., Ltd.
4.18%
CSPC Pharmaceutical Group Ltd.
4.09%
Scholar Rock Holding Corp.
2.47%
ETF 2
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Advertisement
Latest news about THNR
Advertisement
Advertisement
